Endometrial hyperplasia historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{Swathi}} | {{CMG}}; {{Swathi}} | ||
==Overview== | ==Overview== | ||
The history of [[endometrial hyperplasia]] | The history of [[endometrial hyperplasia]] goes back to the 1900s. Initially [[Endometrial cancer|endometrial carcinoma]] was discovered and with the development of histological grades, [[endometrial hyperplasia]] was explored.The association between [[estrogen]] and development of [[endometrial cancer]] was first reported in the 1970s. During this time, the incidence of [[endometrial cancer]] significantly increased between 1970 and 1975 following the introduction of [[estrogen]] replacement therapy. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 15: | Line 15: | ||
===Landmark Events in the Development of Treatment Strategies=== | ===Landmark Events in the Development of Treatment Strategies=== | ||
The current use of [[estrogen]] therapy (ET) and [[estrogen]]-[[progestin]] therapy (EPT) is the end result of many years of research and clinical practice. | The current use of [[estrogen]] therapy (ET) and [[estrogen]]-[[progestin]] therapy (EPT) is the end result of many years of research and clinical practice. | ||
* The history of [[estrogen]] | * The history of [[estrogen]] goes back to 1900s, when [[ovarian]] extracts were used for treatment of [[dysmenorrhea]] and [[amenorrhea]]. | ||
* In 1923, researchers isolated | * In 1923, researchers isolated the use of [[ovarian]] extract. | ||
* In the late 1920s researchers evaluated the impact of [[ovarian]] extracts on [[menopausal]] symptoms. | * In the late 1920s researchers evaluated the impact of [[ovarian]] extracts on [[menopausal]] symptoms. | ||
* In 1928, the first commercially available injectable [[estrogen]] was developed. | * In 1928, the first commercially available injectable [[estrogen]] was developed. | ||
* In 1942, Ayerst Laboratories commercially introduced the first orally active [[estrogen]], Premarin (conjugated [[estrogens]]) | * In 1942, Ayerst Laboratories commercially introduced the first orally active [[estrogen]], Premarin (conjugated [[estrogens]]) in the United States. | ||
* In the mid-1970s, researchers recognized the association between unopposed [[estrogen]] therapy and [[endometrial cancer]]. | * In the mid-1970s, researchers recognized the association between unopposed [[estrogen]] therapy and [[endometrial cancer]]. | ||
* In the following decades, it was observered that long-term [[estrogen]] therapy and [[estrogen]] [[progestin]] therapy use was associated with a small increase in the risk of [[breast cancer]]. | * In the following decades, it was observered that long-term [[estrogen]] therapy and [[estrogen]] [[progestin]] therapy use was associated with a small increase in the risk of [[breast cancer]]. | ||
* In 1990s, [[estrogen]] therapy and [[estrogen]] [[progestin]] therapy was prescribed for the prevention and the treatment of [[menopausal]] symptoms. | * In 1990s, [[estrogen]] therapy and [[estrogen]] [[progestin]] therapy was prescribed for the prevention and the treatment of [[menopausal]] symptoms. | ||
* In 2002, the [[estrogen]] [[progestin]] therapy was | * In 2002, the [[estrogen]] [[progestin]] therapy was withdrawn because of small increases in the risk of [[breast cancer]] and [[CHD]]. | ||
* In 2004, the [[estrogen]] therpay arm of the WHI was also prematurely discontinued, | * In 2004, the [[estrogen]] therpay arm of the Women's Health Initiative (WHI) was also prematurely discontinued. | ||
* The WHI reported, estrogen therapy had no effect on [[CHD]] risk and increased the risk of [[stroke]] and [[Deep vein thrombosis|deep venous thrombosis]] ([[DVT]]) in this population.<ref name="pmid11570312">{{cite journal |vauthors=Brucker C |title=Controlled trial with a monthly combination injectable contraceptive in Europe |journal=Gynecol. Endocrinol. |volume=15 Suppl 3 |issue= |pages=11–4 |date=August 2001 |pmid=11570312 |doi= |url=}}</ref><ref name="pmid1186789">{{cite journal |vauthors=Smith DC, Prentice R, Thompson DJ, Herrmann WL |title=Association of exogenous estrogen and endometrial carcinoma |journal=N. Engl. J. Med. |volume=293 |issue=23 |pages=1164–7 |date=December 1975 |pmid=1186789 |doi=10.1056/NEJM197512042932302 |url=}}</ref><ref name="pmid15845914">{{cite journal |vauthors=Davis SR, Dinatale I, Rivera-Woll L, Davison S |title=Postmenopausal hormone therapy: from monkey glands to transdermal patches |journal=J. Endocrinol. |volume=185 |issue=2 |pages=207–22 |date=May 2005 |pmid=15845914 |doi=10.1677/joe.1.05847 |url=}}</ref><ref name="pmid9421200">{{cite journal |vauthors=Ettinger B |title=Overview of estrogen replacement therapy: a historical perspective |journal=Proc. Soc. Exp. Biol. Med. |volume=217 |issue=1 |pages=2–5 |date=January 1998 |pmid=9421200 |doi= |url=}}</ref><ref name="pmid171569">{{cite journal |vauthors=Ziel HK, Finkle WD |title=Increased risk of endometrial carcinoma among users of conjugated estrogens |journal=N. Engl. J. Med. |volume=293 |issue=23 |pages=1167–70 |date=December 1975 |pmid=171569 |doi=10.1056/NEJM197512042932303 |url=}}</ref><ref name="pmid7421945">{{cite journal |vauthors=Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR |title=Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen |journal=N. Engl. J. Med. |volume=303 |issue=21 |pages=1195–8 |date=November 1980 |pmid=7421945 |doi=10.1056/NEJM198011203032102 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 15:24, 3 May 2019
|
Endometrial hyperplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Endometrial hyperplasia historical perspective On the Web |
|
American Roentgen Ray Society Images of Endometrial hyperplasia historical perspective |
|
Risk calculators and risk factors for Endometrial hyperplasia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Swathi Venkatesan, M.B.B.S.[2]
Overview
The history of endometrial hyperplasia goes back to the 1900s. Initially endometrial carcinoma was discovered and with the development of histological grades, endometrial hyperplasia was explored.The association between estrogen and development of endometrial cancer was first reported in the 1970s. During this time, the incidence of endometrial cancer significantly increased between 1970 and 1975 following the introduction of estrogen replacement therapy.
Historical Perspective
Discovery
- The earliest descriptions of endometrial cancer were reported in the early 1900s.
- The association between estrogen and development of endometrial cancer was first reported in the 1970s when the incidence of endometrial cancer significantly increased between 1970 and 1975 following the introduction of estrogen replacement therapy.[1]
- Surgical staging of endometrial cancer was first suggested in 1988 and was later revised in 2009.[2]
- The first laparoscopic hysterectomy was reported in 1992.[3]
Landmark Events in the Development of Treatment Strategies
The current use of estrogen therapy (ET) and estrogen-progestin therapy (EPT) is the end result of many years of research and clinical practice.
- The history of estrogen goes back to 1900s, when ovarian extracts were used for treatment of dysmenorrhea and amenorrhea.
- In 1923, researchers isolated the use of ovarian extract.
- In the late 1920s researchers evaluated the impact of ovarian extracts on menopausal symptoms.
- In 1928, the first commercially available injectable estrogen was developed.
- In 1942, Ayerst Laboratories commercially introduced the first orally active estrogen, Premarin (conjugated estrogens) in the United States.
- In the mid-1970s, researchers recognized the association between unopposed estrogen therapy and endometrial cancer.
- In the following decades, it was observered that long-term estrogen therapy and estrogen progestin therapy use was associated with a small increase in the risk of breast cancer.
- In 1990s, estrogen therapy and estrogen progestin therapy was prescribed for the prevention and the treatment of menopausal symptoms.
- In 2002, the estrogen progestin therapy was withdrawn because of small increases in the risk of breast cancer and CHD.
- In 2004, the estrogen therpay arm of the Women's Health Initiative (WHI) was also prematurely discontinued.
- The WHI reported, estrogen therapy had no effect on CHD risk and increased the risk of stroke and deep venous thrombosis (DVT) in this population.[4][5][6][7][8][9]
References
- ↑ Jick H, Walker AM, Rothman KJ (1980). "The epidemic of endometrial cancer: a commentary". Am J Public Health. 70 (3): 264–7. PMC 1619376. PMID 7356090.
- ↑ Creasman W (2009). "Revised FIGO staging for carcinoma of the endometrium". Int J Gynaecol Obstet. 105 (2): 109. doi:10.1016/j.ijgo.2009.02.010. PMID 19345353.
- ↑ Childers JM, Surwit EA (1992). "Combined laparoscopic and vaginal surgery for the management of two cases of stage I endometrial cancer". Gynecol Oncol. 45 (1): 46–51. PMID 1534780.
- ↑ Brucker C (August 2001). "Controlled trial with a monthly combination injectable contraceptive in Europe". Gynecol. Endocrinol. 15 Suppl 3: 11–4. PMID 11570312.
- ↑ Smith DC, Prentice R, Thompson DJ, Herrmann WL (December 1975). "Association of exogenous estrogen and endometrial carcinoma". N. Engl. J. Med. 293 (23): 1164–7. doi:10.1056/NEJM197512042932302. PMID 1186789.
- ↑ Davis SR, Dinatale I, Rivera-Woll L, Davison S (May 2005). "Postmenopausal hormone therapy: from monkey glands to transdermal patches". J. Endocrinol. 185 (2): 207–22. doi:10.1677/joe.1.05847. PMID 15845914.
- ↑ Ettinger B (January 1998). "Overview of estrogen replacement therapy: a historical perspective". Proc. Soc. Exp. Biol. Med. 217 (1): 2–5. PMID 9421200.
- ↑ Ziel HK, Finkle WD (December 1975). "Increased risk of endometrial carcinoma among users of conjugated estrogens". N. Engl. J. Med. 293 (23): 1167–70. doi:10.1056/NEJM197512042932303. PMID 171569.
- ↑ Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR (November 1980). "Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen". N. Engl. J. Med. 303 (21): 1195–8. doi:10.1056/NEJM198011203032102. PMID 7421945.